Tri Locum Partners LP 13F: Quarter-over-Quarter Portfolio Changes
Tri Locum Partners LP reported a disclosed portfolio value of approximately $712.5 million in its latest SEC Form 13F-HR filing for Q1 2026, down 7.5% quarter on quarter. Over the quarter, the fund initiated 6 new positions, bought more shares in 3 holdings, trimmed 8 holdings, and exited 4 positions.
Tri Locum Partners LP's top buy was a new stake in Intuitive Surgical INC (ISRG) , equal to 9.9% of the disclosed portfolio. Its top sell was Danaher (DHR) . The fund exited the position completely after it had accounted for 10.3% of the previous portfolio.
New PositionsQ1 2026
Securities disclosed for the first time in Q1 2026 that were not present in the prior 13F-HR filing.
| Company | Ticker | Initial Portfolio Weight | History |
|---|---|---|---|
| INTUITIVE SURGICAL INC | ISRG | 9.9% | History → |
| THERMO FISHER SCIENTIFIC INC | TMO | 9.1% | History → |
| VERTEX PHARMACEUTICALS | VRTX | 8.1% | History → |
| JAZZ PHARMACEUTICALS PLC | JAZZ | 4.2% | Holders → |
| TARSUS PHARMACEUTICALS INC | TARS | 2.5% | Holders → |
| DEFINIUM THERAPEUTICS INC | DFTX | 1.0% | Holders → |
Top BuysQ1 2026
The fund's top buys among existing positions in Q1 2026. Ranked by portfolio-weight impact, with the percentage of additional shares shown separately.
| Company | Ticker | Portfolio Weight Change | More Shares | History |
|---|---|---|---|---|
| DEXCOM INC | DXCM | +2.5% | +65.6% | History → |
| MADRIGAL PHARMACEUTICALS INC | MDGL | +1.1% | +20.1% | History → |
| NUVALENT INC | NUVL | +0.4% | +0.4% | History → |
Top SellsQ1 2026
The fund's top sells among positions it retained in Q1 2026. Ranked by portfolio-weight impact. Full exits are listed separately.
| Company | Ticker | Portfolio Weight Change | Shares Sold | History |
|---|---|---|---|---|
| DIANTHUS THERAPEUTICS IN | DNTH | -1.6% | 76.6% | Holders → |
| AXSOME THERAPEUTICS | AXSM | -3.3% | 69.2% | Holders → |
| UNITED THERAPEUTICS CORP DEL | UTHR | -1.8% | 41.8% | History → |
| JOHNSON & JOHNSON | JNJ | -2.0% | 31.3% | History → |
| TEVA PHARMACEUTICAL INDS LTD | TEVA | -1.5% | 28.9% | History → |
| ARGENX SE | ARGX | -0.9% | 16.0% | Holders → |
| ASCENDIS PHARMA A/S | SYN_04351P101 | 0.9% | 3.7% | Holders → |
| ELI LILLY & CO | LLY | -0.9% | 2.4% | History → |
Full ExitsQ1 2026
Positions present in the prior 13F-HR filing that no longer appear in Q1 2026.
| Company | Ticker | Last-Reported Portfolio Weight |
|---|---|---|
| DANAHER | DHR | 10.3% |
| BOSTON SCIENTIFIC CORP | BSX | 6.4% |
| IONIS PHARMACEUTICALS INC | IONS | 5.7% |
| VERA THERAPEUTICS INC | VERA | 5.3% |
Net Portfolio Value ChangeQ1 2026
- $0.8BPrior quarter
- $0.7BCurrent quarter
- $-0.1BNet delta
- -7.5%% change
Methodology & FAQ
How Tri Locum Partners LP Quarterly Changes Are Computed
All deltas are sourced from sequential SEC Form 13F-HR filings for Tri Locum Partners LP: each row joins the most recent filing against the immediately preceding quarterly filing for the same fund. Share-count changes reflect reported trading activity, while portfolio weights can also move because of market price changes. Portfolio weights are normalized to exclude listed options for comparability. A complete description — including how confidential treatment filings are handled — is documented in the Methodology.
What stocks did Tri Locum Partners LP buy in Q1 2026?
In Q1 2026, Tri Locum Partners LP initiated 6 new positions (INTUITIVE SURGICAL INC (ISRG), THERMO FISHER SCIENTIFIC INC (TMO), VERTEX PHARMACEUTICALS (VRTX), JAZZ PHARMACEUTICALS PLC (JAZZ), TARSUS PHARMACEUTICALS INC (TARS), DEFINIUM THERAPEUTICS INC (DFTX)); bought more shares of DEXCOM INC (DXCM), MADRIGAL PHARMACEUTICALS INC (MDGL), NUVALENT INC (NUVL).
What stocks did Tri Locum Partners LP sell in Q1 2026?
In Q1 2026, Tri Locum Partners LP fully sold 4 positions (DANAHER (DHR), BOSTON SCIENTIFIC CORP (BSX), IONIS PHARMACEUTICALS INC (IONS), VERA THERAPEUTICS INC (VERA)); reduced holdings in DIANTHUS THERAPEUTICS IN (DNTH), AXSOME THERAPEUTICS (AXSM), UNITED THERAPEUTICS CORP DEL (UTHR), JOHNSON & JOHNSON (JNJ), TEVA PHARMACEUTICAL INDS LTD (TEVA) — the largest 5 of 8 reductions.
Which positions did Tri Locum Partners LP initiate in Q1 2026?
Tri Locum Partners LP established 6 new positions in Q1 2026: INTUITIVE SURGICAL INC (ISRG, 9.9%), THERMO FISHER SCIENTIFIC INC (TMO, 9.1%), VERTEX PHARMACEUTICALS (VRTX, 8.1%), JAZZ PHARMACEUTICALS PLC (JAZZ, 4.2%), TARSUS PHARMACEUTICALS INC (TARS, 2.5%), DEFINIUM THERAPEUTICS INC (DFTX, 1.0%).
Which existing positions saw the largest allocation increases for Tri Locum Partners LP in Q1 2026?
Of 3 existing positions with share-count increases in Q1 2026, the largest were: DEXCOM INC (DXCM, +2.5% weight, +65.6% shares), MADRIGAL PHARMACEUTICALS INC (MDGL, +1.1% weight, +20.1% shares), NUVALENT INC (NUVL, +0.4% weight, +0.4% shares).
Which positions did Tri Locum Partners LP fully exit in Q1 2026?
Tri Locum Partners LP fully exited 4 positions in Q1 2026: DANAHER (DHR, last-reported weight 10.3%), BOSTON SCIENTIFIC CORP (BSX, last-reported weight 6.4%), IONIS PHARMACEUTICALS INC (IONS, last-reported weight 5.7%), VERA THERAPEUTICS INC (VERA, last-reported weight 5.3%).
Which existing positions saw the largest allocation reductions for Tri Locum Partners LP in Q1 2026?
Of 8 existing positions with share-count reductions in Q1 2026, the largest were: DIANTHUS THERAPEUTICS IN (DNTH, -1.6% weight, -76.6% shares), AXSOME THERAPEUTICS (AXSM, -3.3% weight, -69.2% shares), UNITED THERAPEUTICS CORP DEL (UTHR, -1.8% weight, -41.8% shares), JOHNSON & JOHNSON (JNJ, -2.0% weight, -31.3% shares), TEVA PHARMACEUTICAL INDS LTD (TEVA, -1.5% weight, -28.9% shares), ARGENX SE (ARGX, -0.9% weight, -16.0% shares), ASCENDIS PHARMA A/S (SYN_04351P101, 0.9% weight, -3.7% shares), ELI LILLY & CO (LLY, -0.9% weight, -2.4% shares).
Do quarter-over-quarter 13F allocation changes constitute explicit trading signals?
No. Quarter-over-quarter changes reflect a combination of active trading and market price movement. A weight increase can result from price appreciation alone, without the manager adding shares. Share-count delta is the cleaner indicator of explicit trading activity. All deltas on this page are sourced from sequential SEC Form 13F-HR filings.